Oral Omega 3 Drusen: A phase II randomized, double-mask study to establish the safety and efficacy of High-Dose Oral Omega 3 in subjects with high-risk drusen secondary to dry age-related macular degeneration 26/03/2013
Description
The objectives of this study are to evaluate the safety and efficacy of High-Dose Oral Omega 3 on the Photoreceptors/Retinal Pigment Epithelium/Bruch’s membrane complex in subjects with high-risk drusen secondary to age-related macular degeneration and to evaluate whether improvement in visual function occurs and progression to advanced stages of AMD is delayed.
Author
Доктор Jordi Monés, M.D., Ph.D.
Номер лицензии COMB: 22.838
Директор
Доктор Медицины и Хирургии
Специалист по Офтальмологии
Специалист по лечению Сетчатки, Макулы и Стекловидного тела
01/01/2015
FOVISTA: Clinical Trial for subfoveal neovascular age-related macular degeneration
19/03/2014
Clinical trial in antiretroviral-naive patients with choroidal neovascularization secondary to AMD
31/03/2014
Phase III Study of Lampalizumab in patients with geographic atrophy secondary to AMD
20/12/2014
MPL4 GA: A phase I study in subjects with geographic atrophy secondary to dry age-related macular degeneration
